The Market Size of Nocturia is anticipated to increase during the study period 2019-2032

"The increase in market size is a direct consequence of an increase in prevalent cases of diabetes, kidney diseases and increased number of older age population in the 7MM"

The Nocturia market report provides current treatment practices, Nocturia emerging drugs, Nocturia market share of the individual therapies, current and forecasted Nocturia market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Nocturia treatment practice/algorithm, market drivers, market barriers and Nocturia unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Nocturia market.

Key takeaways from the Nocturia Market Research Report

• According to DelveInsight. Nocturia affects both men and women depending upon their age and causes.

• Nocturia is often identified as the most unpleasant of all urinary symptoms, as well as one of the most popular. It is estimated that it affects ~50 million people in the United States, with 10 million actually diagnosed with nocturia (Leslie et al, 2021).

• The leading Nocturia Market Companies include Ferring Pharmaceuticals, Wellesley Pharmaceuticals, Sanwa Kagaku Kenkyusho / Kyorin Pharmaceutical, and others.

• Promising Nocturia Pipeline Therapies include Nocdurna (desmopressin acetate sublingual tablets), Nocturol, SK-1404, and others.

For more insights into the Nocturia Market Landscape, visit Nocturia Market Therapeutics Landscape @ https://www.delveinsight.com/sample-request/nocturia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Nocturia Overview
The need for a patient to get up at night on a regular basis to urinate is called Nocturia. To be considered as a nocturnal void, a period of sleep must precede and follow the urinary episode. This means that when identifying Nocturia episodes, the first morning void is ignored.

Recent Developmental Activities in the Nocturia Treatment Landscape

• In December 2007, the US FDA issued a warning on the use of desmopressin but later on, based on the safety and efficacy data, in March 2017, the US FDA approved Noctiva (desmopressin acetate), a nasal spray for adults who awaken at least two times per night to urinate due to a condition known as nocturnal polyuria (overproduction of urine during the night). Noctiva is the first FDA-approved treatment for this condition. Noctiva was approved with a boxed warning and a Medication Guide because it can cause hyponatremia. Desmopressin is a man-made form of vasopressin and is used to replace a low level of vasopressin. Noctiva's efficacy was established in two 12-week, randomized, placebo-controlled trials in 1,045 patients 50 years of age and older with nocturia due to nocturnal polyuria. Although these trials showed a small reduction in the average number of night-time urinations with Noctiva compared to placebo, more patients treated with Noctiva were able to at least halve their number of night-time urinations, and patients treated with Noctiva had more nights with one or fewer night-time urinations. Less than a year after launching Noctiva in the US, Avadel said that it will no longer market the product.

• Later on, in June 2018, the US FDA licensed Nocdurna (desmopressin acetate sublingual tablets; Ferring) for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void. The recommended dose for women is lower in comparison to men, i.e., 27.7mcg (for women) and 55.3mcg (for men). It also got a green signal from the European Commission in 2016 for the symptomatic treatment of nocturia due to idiopathic nocturnal polyuria in adults. The US FDA approved Nocdurna based on three double-blind, placebo-controlled trials and one open-label extension trial of up to 3 years in patients ≥18 years old. It is worth mentioning that Nocdurna also carries a Boxed Warning for hyponatremia.

Nocturia Epidemiology Segmentation in the 7MM

• Total Nocturia Prevalent Cases

• Total Nocturia Type-Specific Prevalent Cases

• Total Nocturia Diagnosed Prevalent Cases

• Total Nocturia Age-specific Prevalent Cases

• Nocturia Treated Cases

To know more information of the Nocturia Epidemiology Segmentation of the report, click here for Nocturia Epidemiology Insights @ https://www.delveinsight.com/sample-request/nocturia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Nocturia Market Insights
Nocturia can be a stressful problem for many individuals, however, can be overcome with adequate management and commitment for a better quality of life. The treatment should be tailored to the underlying causes of nocturia and should include lifestyle modifications and, if required, pharmacological therapy. Pharmacological options can be used alone or combined with some of the behavioral modifications, which have been proven to be effective. Several studies have confirmed that the medication only works as long as it is taken, once off the medication, relapses are quite common.

Nocturia Emerging Therapy Assessment
As of now the clinical development activity around Nocturia remains pretty scarce as not many companies are active with their pipeline with respect to this condition. Key players such as Wellesly Pharmaceuticals (Nocturol), Sanwa Kagaku Kenkyusho/ Kyorin Pharmaceutical (SK-1404), Vantia Therapeutics (Fedovapagon (VA106483), might influence the market size during the forecast period [2022-2032].

Browse More Related Reports of the Nocturia Market Research Reports, click here for Nocturia Market Forecast @ https://www.delveinsight.com/sample-request/nocturia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Nocturia Market Report

• Coverage- 7MM

• Nocturia Market Companies- Ferring Pharmaceuticals, Wellesley Pharmaceuticals, Sanwa Kagaku Kenkyusho / Kyorin Pharmaceutical, and others.

• Nocturia Pipeline Therapies- Nocdurna (desmopressin acetate sublingual tablets), Nocturol, SK-1404, and others

• Nocturia Market Dynamics: Nocturia Market Drivers and Barriers

• Nocturia Market Access and Reimbursement, Unmet Needs, Future Perspective

Read the Full Research Report of the Nocturia Market Forecast Report, click here for Nocturia Market Drivers and Barriers @ https://www.delveinsight.com/sample-request/nocturia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Executive Summary of Nocturia
3. Competitive Intelligence Analysis for Nocturia
4. Nocturia: Market Overview at a Glance
5. Nocturia: Disease Background and Overview
6. Patient Journey
7. Nocturia Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Nocturia Unmet Needs
10. Key Endpoints of Nocturia Treatment
11. Nocturia Marketed Products
12. Nocturia Emerging Therapies
13. Nocturia: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Nocturia Market Outlook
16. Access and Reimbursement Overview of Nocturia
17. KOL Views
18. Nocturia Market Drivers
19. Nocturia Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

Consult with our Business Expert regarding "Nocturia Market Landscape" @ https://www.delveinsight.com/sample-request/nocturia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

List of Trending Market Reports in 2023

Healthcare Partner Identification Services @ https://www.delveinsight.com/consulting/partner-identification-services

Medical Marijuana Market @ https://www.delveinsight.com/report-store/medical-marijuana-market-insight

Oncolytic Virus Cancer Therapy Pipeline @ https://www.delveinsight.com/report-store/oncolytic-virus-cancer-therapy-pipeline-insight-2021

Overactive Bladder Syndrome Market @ https://www.delveinsight.com/report-store/overactive-bladder-market

Pediatric Growth Hormone Deficiency PGHD Market @ https://www.delveinsight.com/report-store/pediatric-growth-hormone-deficiency-market

Percutaneous Arterial Closure Device Market @ https://www.delveinsight.com/report-store/percutaneous-arterial-closure-device-market

Ranibizumab Biosimilars Insight @ https://www.delveinsight.com/report-store/ranibizumab-biosimilars-insight

Schistosomiasis Market @ https://www.delveinsight.com/report-store/schistosomiasis-market

Stem Cell Market @ https://www.delveinsight.com/report-store/stem-cell-market

Superficial Punctate Keratitis Market @ https://www.delveinsight.com/report-store/superficial-punctate-keratitis-market

Technical Due Diligence @ https://www.delveinsight.com/consulting/due-diligence-services

Transient Ischemic Attack Market @ https://www.delveinsight.com/report-store/transient-ischemic-attack-market

Wilms Tumor Market @ https://www.delveinsight.com/report-store/wilms-tumor-market

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Contact Us

Yash Bhardwaj

info@delveinsight.com

This release was published on openPR.